Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
about
The cost-effectiveness of Vancouver's supervised injection facilityHepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factorsAgent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C InfectionsEnhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.Hepatitis C transmission and treatment in contact networks of people who inject drugs.High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users.Associations between injection risk and community disadvantage among suburban injection drug users in southwestern Connecticut, USA.The long-term effectiveness of methadone maintenance treatment in prevention of hepatitis C virus among illicit drug users: a modeling study.Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs.Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs.Staying safe from hepatitis C: engaging with multiple priorities.Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first?The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.A time since onset of injection model for hepatitis C spread amongst injecting drug users.Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots.Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference?Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services.Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.The extent of injection site infection in injecting drug users: findings from a national surveillance study.Trust, disruption and responsibility in accounts of injecting equipment sharing and hepatitis C riskA Mathematical Model for Assessing the Impact of Intravenous Drug Misuse on the Dynamics of HIV and HCV within Correctional Institutions
P2860
Q24657903-B5F078FB-11A2-4305-9CCE-4BC22C754433Q26853671-521AC9FB-A2D8-4C5E-A8B8-811B9F4CAA45Q28548643-6AD19FCB-F8EC-40D6-B794-D7FCDE988F83Q28713638-AD9DEA06-663B-4882-A741-48E85FFA1619Q33824723-0C1706E4-8301-4C15-A047-F6535C53FF27Q35040866-14BD7E84-8437-4492-B8EB-687A1A59CC41Q36123087-EA581CA9-28C9-48A6-999B-BB6CBA338803Q37196683-0A7376B4-AD41-4DD7-85C9-F1BC11311975Q37568363-462555E6-DA2D-425A-A161-30B567B63C22Q37663322-8CBAAF0A-360D-4E79-A604-81F2E8DBE0AFQ38255693-4B662C28-0C23-4205-8201-B651D78424F0Q38573508-E9E47D8E-1216-4517-81FB-78B49A2F7BF2Q38769157-94FAAC5C-5757-4D6B-8D17-EF38D8AC0AFDQ39047581-84A52512-AACB-4937-A682-1E9A5C93C6EEQ39050461-DAB7AD04-FE42-4C6D-AF08-0FE81BAE6D64Q39050468-0CD1AC73-A0E4-4574-AA50-8818F4DCE039Q40891018-732C7AE1-48E3-4157-9058-180B50366587Q41546485-2E443496-054C-428E-A88D-DF4DC274EE70Q42197246-AAEFE9B0-F4D8-4A8B-91A5-79C71B3FAF86Q42602432-5763566D-0DA9-43AD-B594-7572E02E6959Q42983662-18D94AAF-BBD5-46DC-B627-F58416273F07Q42996974-3127FE05-67C3-4584-9649-B09DAC6D3D83Q43047432-5618F076-525B-4140-9321-7521E30CB9BFQ44001612-9D7B2184-86D2-4B75-A46A-AACBAD225F41Q45363548-85325741-60E1-4614-BAF6-808C99634033Q47191023-46D08544-32A9-485B-829B-5C5F2F1DA721Q47603693-E4C46E76-0FEF-4703-B0E0-F96AC65DE172Q47619711-F9FCFDAC-D6E1-4A62-96B4-E9AD4B96996EQ57773664-5F65C82B-83B7-4DF2-8AFB-43F13C6542D6Q58905366-515D6530-E793-4A6B-82CD-4D7AD2829018
P2860
Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Modelling the impact on Hepati ...... ge sharing: London case study.
@en
Modelling the impact on Hepati ...... ge sharing: London case study.
@nl
type
label
Modelling the impact on Hepati ...... ge sharing: London case study.
@en
Modelling the impact on Hepati ...... ge sharing: London case study.
@nl
prefLabel
Modelling the impact on Hepati ...... ge sharing: London case study.
@en
Modelling the impact on Hepati ...... ge sharing: London case study.
@nl
P2860
P50
P356
P1476
Modelling the impact on Hepati ...... nge sharing: London case study
@en
P2093
P2860
P304
P356
10.1093/IJE/DYL276
P407
P577
2007-01-11T00:00:00Z